1 min read
Add as a preferred source on GoogleRevolution Medicines Shares Rise About 6% After Q3 Results Beat
The company reaffirmed its 2026 GAAP operating expense range of $2.1 billion to $2.2 billion and posted a $1.90 per-share loss.
Revolution Medicines shares climbed about 6% in after-hours trading Wednesday, Nov. 4, after the oncology drug developer posted third-quarter results that topped expectations for both revenue and earnings.
The company reaffirmed its 2026 forecast for generally accepted accounting principles (GAAP) operating expenses of $2.1 billion to $2.2 billion. Its GAAP loss was $1.90 per share in the third quarter.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.